ribonucleotide reductase


Also found in: Acronyms, Wikipedia.

ri·bo·nu·cle·o·tide re·duc·tase

a protein complex that converts ribonucleotide diphosphates (NDPs) such as ADP and CDP to 2'-deoxyribonucleotide diphosphates (dNDPs) such as dADP and dCDP. This complex requires thioredoxin, thioredoxin reductase, and NADPH. It is crucial for DNA synthesis.

ribonucleotide reductase

(1) Ribonucleoside-diphosphate reductase, EC 1.17.4.1. 
(2) Ribonucleoside-triphosphate reductase, EC 1.17.4.2.
References in periodicals archive ?
The formulation investigated contains Calando's proprietary delivery technology and utilizes RNA interference in cancer cells with an siRNA duplex targeting the M2 subunit of ribonucleotide reductase, a well-established cancer target.
The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target, and Calando's proprietary siRNA polymer delivery system.
The article titled "RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo" was published online today in the peer-reviewed journal Anti-Cancer Drugs and will appear in print in the April issue.
The formulation being advanced to clinical trials by Calando contains Calando's proprietary delivery technology and utilizes RNA interference in cancer cells with an siRNA duplex targeting the M2 subunit of ribonucleotide reductase, a well-established cancer target.
Calando's proprietary siRNA targets the M2 subunit of ribonucleotide reductase, a well-established cancer target.
The paper, entitled "Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo," was published in the April 1 edition of Clinical Cancer Research, a journal published by the American Association of Cancer Research (AACR).
GTI-2040 is an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase, an activity that is essential for DNA synthesis and tumor growth.
The paper, entitled "Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA," was published online in the Early Edition of the PNAS.
Hormone Refractory Prostate Cancer: Data will be presented from an ongoing clinical trial of GTI-2501, an antisense compound targeting the R1 gene, the large subunit of ribonucleotide reductase, which is essential for DNA synthesis and cell proliferation.
The formulation investigated contains Calando's proprietary delivery technology with an siRNA duplex targeting the M2 subunit of ribonucleotide reductase, a well-established cancer target.
The article titled "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment', to be published in the May issue of Oncology Reports (Volume 15, Issue 5, Pages 1299-1304), presents a case study from a National Cancer Institute (NCI) sponsored Phase II clinical trial of GTI-2040 in combination with capecitabine in metastatic breast cancer.